HALO

Over the past six months, Halozyme's stock (HALO) has increased by 81.51%. Key events include record second-quarter 2026 results reported on August 6, 2026, which exceeded estimates and led to a 20.24% stock increase, with EPS of $2.28 and revenue of $481 million. On August 18, 2026, the appointment of Dannielle Appelhans to the Board of Directors resulted in a 2.58% stock increase. In September 2026, Halozyme announced its participation in upcoming investor conferences. On September 16, 2026, the company announced a proposed offering of $1.05 billion of convertible senior notes due 2033, which was upsized to $1.3 billion on September 17, leading to a 1.3% rise in shares. The private offering of $1.5 billion aggregate principal amount of 1.50% Convertible Senior Notes due 2033 was completed on September 22, 2026. On September 24, 2026, Halozyme Therapeutics reached a new 52-week high of $116.85.